1. Argentina Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Laboratorios Richmond SACIF Class B

Laboratorios Richmond SACIF Class B

1.01
USD
-0.09
(-8.18%)
0.11EPS
10.12P/E
83.32MMarket Cap
Laboratorios Richmond SACIF Class B
BYMA:RICHD
(Buenos Aires Stock Exchange)

Recent

price

1.01

P/E

ratio

10.12

div

yld

-0.52%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
ARS
28.09
34.64
65.56
115.56
400.88
711.99
1,052.49
1,495.38
1,569.38
1,625.18
Revenue per Share
0.86
-4.11
1.96
9.09
14.27
6.3
-292.62
388.45
38.24
151.2
Basic EPS, GAAP
-1.72
-7.08
-5.65
-13.61
-52.94
-455.05
-393.81
-51.92
-649.71
-131.56
Free Cash Flow per Basic Share
0.71
0.26
- -
- -
1.44
8.44
- -
- -
32.58
-7.78
Dividend per Share
15.52
20.03
33.95
63.19
127.7
389.11
608.1
1,047.45
1,133.05
1,459.37
Book Value per Share
12.8
14.56
24.92
44.11
79.59
221.24
190.21
554.85
543
753.04
Tangible Book Value per Share
57
81
81
81
81
81
81
81
81
81
Basic Weighted Avg Shares
1,591
2,795
5,303
9,330
32,366
57,518
84,989
120,754
126,726
131,236
Sales/Revenue/Turnover
12.41
6.54
20.12
24.96
13.88
16.18
13.57
17.75
26.26
18.45
Operating Margin (%)
51
82
186
255
673
2,279
5,082
9,569
10,568
12,173
Depreciation Expense
49
-332
159
734
1,152
509
-23,629
31,368
3,088
12,210
Net Income, GAAP
53.4
- -
40.28
35.87
57.57
80.06
- -
16.68
73.6
31.57
Effective Tax Rate (%)
3.06
-11.87
2.99
7.87
3.56
0.88
-27.8
25.98
2.44
9.3
Profit Margin (%)
943
1,103
906
2,802
11,899
15,589
-10,688
15,500
742
-8,235
Working Capital
38
148
152
1,481
18,814
57,732
18,020
164,485
186,580
195,154
LT Debt
1,253
1,709
2,791
5,202
10,471
31,818
49,982
85,966
93,039
119,011
Total Equity
- -
- -
22.22
25.74
9.25
2.83
- -
8.8
2.86
5.3
Return on Invested Capital (%)
- -
- -
9.03
18.85
8.6
2.14
- -
21.39
2.38
8.26
Return on Capital (%)
- -
-23.11
7.27
18.71
14.95
2.44
-58.69
46.93
3.51
12.65
Return on Common Equity (%)

Capital Structure

ARS

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
59,804
58,824
48,354
LT Borrowings
166,365
157,548
174,047
LT Finance Leases
20,214
19,415
21,107
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
81
81
81
Market Capitalization
163,360
- -
123,602

Working Capital

ARS

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
120,538
111,178
99,318
Cash, Cash Equivalents & STI
14,466
3,238
3,874
Accounts Receivable, Net
58,563
59,272
45,615
Inventories
41,666
43,692
45,026
Total Current Liabilities
119,795
113,619
107,553
Payables & Accruals
- -
- -
- -
ST Debt
59,804
58,824
48,354
Deferred Revenue
- -
- -
- -

Growth Rates

ARS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
88.49%
8.23%
Free Cash Flow
- -
419.99%
1,151.36%
Net Income, GAAP
- -
-1,012.92%
-90.16%
Sales/Revenue/Turnover
- -
83.88%
4.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

ARS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,416
23,644
25,971
33,954
120,754
2025
35,828
37,946
30,878
38,816
126,726
2026
28,744
32,798
- -
- -
- -

Quarterly Earnings Per Share

ARS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
132.8
51.08
90.59
72.22
388.45
2025
93.03
-43.32
-113.57
109.89
38.24
2026
262.03
-107.15
- -
- -
- -

Quarterly Dividends Per Share

ARS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
-10.15
2.37
32.58
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Laboratorios Richmond S.A.C.I.F. (RICH.BA) develops and manufactures pharmaceutical products including generics, biosimilars, and licensed technologies; its core portfolio encompasses antiretroviral treatments for HIV, oncology and oncohematology drugs, cardiometabolic therapies such as antihypertensives (Losartan/Tacardia, Telmisartan/Telcardia), hypolipidemics (Atorvastatin/Vastina), diuretics, antiplatelet agents and hypoglycemics, neurological and psychiatric medications including analgesics, antipsychotics, antidepressants, anti-dementia drugs, antiepileptics, hypnotics and multiple sclerosis treatments, as well as ophthalmological solutions like Ganciclovir and innovative fixed-dose combinations in user-friendly packaging. Founded in 1935 and headquartered in Buenos Aires, Argentina, with manufacturing facilities in Pilar, Argentina, and Bogotá, Colombia, plus commercial operations in Chile, Paraguay, Mexico and Uruguay, the company serves physicians, pharmacists, health institutions and patients across 25 countries in Latin America, Africa, Asia and the Middle East. In July 2024, Laboratorios Richmond launched Yriviak, its bevacizumab similar biological for neovascular age-related macular degeneration, marking its second such product and first in ophthalmology following ANMAT approval in November 2023; the company also secured approval for adalimumab similar biological Armixa in December 2023, with launch planned soon after, while continuing technology transfers and regional expansions including a new entity in Uruguay.